Application Factor Xa Inhibitors In Patients With Acute Coronary Syndromes, Felling Shaaban Worship (completed) Safety Observation

Purpose：To evaluate whether the oral direct factor Xa inhibitorrivaroxaban(Xarelto) is safe or efficient in the patients with acute coronarysyndrome.Material and method：80patients with acute coronary syndrome (includingunstable angina, non-ST segment elevation myocardial infarction and ST segmentelevation myocardial infarction) randomly divided into rivaroxaban(Xarelto)group and sulfonic sodium liver decanoic (Android) group. Xarelto group:patients with no PCI operation, direct to the5mg,qd,po,10th consecutive; therest patients direct to the5mg,qd,po, after PCI operation10th consecutive.Android group: with sodium sulfonated1.25-2.5mg qd, a subcutaneous injection,use7d; PCI patients, surgery to unfractionated heparin. Respectively，patientsbefore and after30d determination of activated partial thromboplastintime(APTT), prothrombin time(PT) and platelet(PLT).During the following-up，all cardiovascular events and adverse drug reaction events are recorded.Results：⑴There are no statistical differences in severe cardiovascular events after30d between the two groups.⑵There are no statistical differences in the change of activated partialthromboplastin time(APTT), prothrombin time(PT) and platelet(PLT) before andafter30d, either in inner group or between the two groups.⑶Adverse drug reaction events are increased to varying degrees, the formationrate of Xarelto group is similar as the one of Android group (P>0.05).Conclusion：The oral direct factor Xa inhibitor rivaroxaban(Xarelto) has little effect oncoagulative fuction as sulfonic sodium liver decanoic dose.for the treatment of patients with acute coronary syndrome, and easy to use.